Canaccord Genuity Maintains Buy on Exact Sciences, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Exact Sciences (NASDAQ:EXAS) but lowers the price target from $100 to $90.
February 22, 2024 | 7:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Exact Sciences but lowers the price target from $100 to $90.
While the maintenance of a Buy rating suggests continued confidence in the company's fundamentals and growth prospects, the reduction in the price target could reflect adjustments in valuation metrics or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially causing minor fluctuations in the stock price. However, the overall positive outlook is likely to support the stock's performance in the near term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100